The applicant/owner of the trademark is registered as PIERIS AG. Organization. Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and so on. NEW DELHI: Stelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, today said it has entered into a long-term agreement with Germany's Pieris AG for worldwide development and commercialisation of a protein molecule, primarily focused on ophthalmology. We're not affiliated with Pieris Ag, we're just tracking patents. Mr. Stephen S. Yoder joined Pieris as Chief Executive Officer in January 2010. The trademarks on file for companies that go by the name of Pieris Ag are Anticalin and Pocket Binding. Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the AACR Annual Meeting. is 10 months 6 days old. Products. Transfer Agent Computershare P.O. Lise-Meitner-Str. Pieris AG Appoints Chief Scientific Officer FREISING-WEIHENSTEPHAN, Germany, June 7, 2010/PRNewswire/ -- Pieris AG announced today that Laurent … Pieris AG-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies… Find 14 researchers and browse 0 departments, publications, full-texts, contact details and general information related to Pieris AG | Freising, Germany | PIERISAG In dit artikel uit de serie tuinplanten lees je alles over de Rotsheide, Pieris japonica, een prachtig bloeiende heester die opvalt met haar jong rood blad dat later naar groen verkleurd. 120. 2 visitors have checked in at Pieris AG. Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin(R) in preclinical studies. Pieris Ag patents Recent patent applications related to Pieris Ag. Innovation Platform for Executives. Foursquare uses cookies to provide you with an optimal experience, to personalize ads that you may see, and to help advertisers measure the … Pieris AG develops and markets Anticalin-brand proteins. Under the terms of the agreement, Pieris will take care of early stages of development in each collaborative programme … Pieris and AstraZeneca announced a broad strategic collaboration in the local delivery of targeted biologics in respiratory disease in May 2017. Pieris Ag is listed as an Agent/Assignee. Resources. This website is estimated worth of $ 8.95 and have a daily income of around $ 0.15. Northern European mid-market buyout firm : United Kingdom : 6630 Fund management: edit It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. Advanced. Wir sind einer der weltweit führenden Glashersteller. Due to their molecular architecture, anticalins offer some distinct advantages over antibodies; Pieris will exploit these advantages in developing new drugs for oncology and inflammatory diseases. Pieris ProteoLab was founded in February 2001 to commercialize anticalins, a novel class of antibody mimetics based on a lipocalin scaffold. Pieris AG announced that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Prior to joining Pieris, from July 2003 to December 2009 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of … Log In. Additional Details: 1000 Ask Question Find a Lawyer. Question: Add details. Aug 2015 – Present 5 years 1 month. Pieris AG. Designed by Elegant Themes | Powered by WordPress The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. Pieris ProteoLab was founded in February 2001 to commercialize anticalins, a novel class of antibody mimetics based on a lipocalin scaffold. [email protected] Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins for the diagnosis and treatment of life-threatening human disorders. They used the trademark attorney firm DibbsBarker to file this trademark. Note: Pieris Ag may have other listings under different names/spellings. As no active threats were reported recently by users, is SAFE to browse. Stock analysis for Pieris Pharmaceuticals Inc (PIRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. EVP Respiratory Argenta Discovery. Try Pro free Solutions. bulk skin care. Search Crunchbase. ANTICALIN: Pieris Ag Lise-Meitner-Str. Ask a Lawyer. Investor Relations Maria Kelman Director of Investor Relations T: +1-857-362-9635 [email protected] Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin candidates. PIERIS with trademark number 1606211 was lodged on 15/02/2014 and has a status of Registered/Protected. Feb 2010 – Jul 2015 5 years 6 months. Resources. Chemicals used in industry and science, namely, conjugates of organic and inorganic chemicals with polypeptides, proteins… Owned by: PIERIS AG Serial Number: 78051017 30, 85354 Freising, Germany, represented by the Executive Board - the “Employer” , and Save. Oxford, United Kingdom. Pricing. PIERIS PROTEOLAB. It is a domain having com extension. Connect to CRM . Assignee: Pieris AG Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora 1 2 next. Datamonitors' Pieris AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Pieris AG since January 2007. 30 Freising-Weihenstephan 85354: Serial Number: 78143412: Aug 2015 – Sep 2017 2 years 2 months.